No change of heart on Avandia: advisor

Australia should resist any bid to ease the heavy prescribing restrictions on controversial diabetes drug rosiglitazone, says a leading expert and government advisor.

Professor Duncan Topliss (pictured), commenting on recent moves to relax restrictions in the US, said the latest re-evaluation of rosiglitazone (Avandia) clinical trial data by the Food and Drug Administration "doesn't exculpate the drug at all